These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7579470)

  • 1. Thalidomide as salvage therapy for chronic graft-versus-host disease.
    Parker PM; Chao N; Nademanee A; O'Donnell MR; Schmidt GM; Snyder DS; Stein AS; Smith EP; Molina A; Stepan DE; Kashyap A; Planas I; Spielberger R; Somlo G; Margolin K; Zwingenberger K; Wilsman K; Negrin RS; Long GD; Niland JC; Blume KG; Forman SJ
    Blood; 1995 Nov; 86(9):3604-9. PubMed ID: 7579470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
    Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
    Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide for the treatment of chronic graft-versus-host disease.
    Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
    N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of thalidomide in chronic refractory graft versus host disease.
    van de Poel MH; Pasman PC; Schouten HC
    Neth J Med; 2001 Aug; 59(2):45-9. PubMed ID: 11476911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature.
    Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR
    Pediatrics; 1999 Apr; 103(4):e44. PubMed ID: 10103336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
    Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide for treatment of patients with chronic graft-versus-host disease.
    Koc S; Leisenring W; Flowers ME; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ
    Blood; 2000 Dec; 96(12):3995-6. PubMed ID: 11090092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe cutaneous ulceration following treatment with thalidomide for GVHD.
    Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K
    Bone Marrow Transplant; 2001 Jan; 27(2):229-30. PubMed ID: 11281398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of thalidomide for CGVHD defended.
    Altomonte V
    Oncol Nurs Forum; 1993 Apr; 20(3):428. PubMed ID: 8497414
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease.
    Bron D
    Curr Opin Oncol; 1994 Jul; 6(4):358-64. PubMed ID: 7803536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide for treatment of graft-versus-host disease.
    Vogelsang GB; Hess AD; Santos GW
    Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of budesonide mouthwash on oral chronic graft versus host disease.
    Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
    Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease.
    Gaziev D; Lucarelli G; Polchi P; Angelucci E; Galimberti M; Giardini C; Baronciani D; Erer B; Sodani P
    Bone Marrow Transplant; 2001 Jan; 27(1):45-51. PubMed ID: 11244437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
    Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.